Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Zsuzsanna Suba. (2015) The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance. Drug Design, Development and Therapy 9, pages 4341-4353.
Read now
Read now
Zsuzsanna Suba. (2014) Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications. OncoTargets and Therapy 7, pages 147-164.
Read now
Read now
Per Eystein Lønning. (2010) Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opinion on Investigational Drugs 19:sup1, pages S19-S30.
Read now
Read now
Articles from other publishers (24)
Aijun Sun, Fengze Cai, Qingping Xiong, Tong Xie, Xiang Li, Yanteng Xie, Ruiyang Luo, Wenwen Hu, Fei Zhong & Shiyan Wang. (2023) Comprehensive pan-cancer investigation: unraveling the oncogenic, prognostic, and immunological significance of Abelson interactor family member 3 gene in human malignancies. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Marina Savic, Ivana Kuzminac & Andrea Nikolic. (2023) Testolactone: The Rise and Fall of a Drug. Drugs and Drug Candidates 2:1, pages 69-94.
Crossref
Crossref
Peng Li, Wenhui Yuan, Ruan Wu, Chuqian Zeng, Ke Li & Ligong Lu. (2022) Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy. Frontiers in Oncology 12.
Crossref
Crossref
Theresa E. Hickey, Luke A. Selth, Kee Ming Chia, Geraldine Laven-Law, Heloisa H. Milioli, Daniel Roden, Shalini Jindal, Mun Hui, Jessica Finlay-Schultz, Esmaeil Ebrahimie, Stephen N. Birrell, Suzan Stelloo, Richard Iggo, Sarah Alexandrou, C. Elizabeth Caldon, Tarek M. Abdel-Fatah, Ian O. Ellis, Wilbert Zwart, Carlo Palmieri, Carol A. Sartorius, Alex Swarbrick, Elgene Lim, Jason S. Carroll & Wayne D. Tilley. (2021) The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer. Nature Medicine 27:2, pages 310-320.
Crossref
Crossref
Anna Tesei & Gabriella Castoria. (2021) Editorial: The Androgen Receptor in Breast Cancer. Frontiers in Endocrinology 11.
Crossref
Crossref
Debora Basile, Marika Cinausero, Donatella Iacono, Giacomo Pelizzari, Marta Bonotto, Maria Grazia Vitale, Lorenzo Gerratana & Fabio Puglisi. (2017) Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. Cancer Treatment Reviews 61, pages 15-22.
Crossref
Crossref
V. Craig Jordan. (2017) Endoxifen: The End, or Are We at the Beginning?. Journal of Clinical Oncology 35:30, pages 3378-3379.
Crossref
Crossref
Elgene Lim, Gerard Tarulli, Neil Portman, Theresa E Hickey, Wayne D Tilley & Carlo Palmieri. (2016) Pushing estrogen receptor around in breast cancer. Endocrine-Related Cancer 23:12, pages T227-T241.
Crossref
Crossref
Evan Simpson & Richard J Santen. (2015) Celebrating 75 years of oestradiol. Journal of Molecular Endocrinology 55:3, pages T1-T20.
Crossref
Crossref
Ping Fan, Philipp Y. Maximov, Ramona F. Curpan, Balkees Abderrahman & V. Craig Jordan. (2015) The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Molecular and Cellular Endocrinology 418, pages 245-263.
Crossref
Crossref
Ruilei Liu, Jie Li, Yuanhui Lai, Yi Liao, Ruiming Liu & Wanshou Qiu. (2015) Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1. International Journal of Biological Macromolecules 81, pages 491-497.
Crossref
Crossref
Karin Elebro, Signe Borgquist, Maria Simonsson, Andrea Markkula, Karin Jirström, Christian Ingvar, Carsten Rose & Helena Jernström. (2015) Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort. Clinical Cancer Research 21:16, pages 3640-3650.
Crossref
Crossref
Piero Sismondi, Marta D’Alonzo, Valentina Elisabetta Bounous, Francesca Quintili, Anna Maria Ferrero, Luca Mariani & Nicoletta Biglia. 2015. Frontiers in Gynecological Endocrinology. Frontiers in Gynecological Endocrinology
179
183
.
V. C. Jordan. (2014) Linking Estrogen-Induced Apoptosis With Decreases in Mortality Following Long-term Adjuvant Tamoxifen Therapy. JNCI Journal of the National Cancer Institute 106:11, pages dju296-dju296.
Crossref
Crossref
J. Bines, R. Dienstmann, R.M. Obadia, L.G.P. Branco, D.C. Quintella, T.M. Castro, P.G. Camacho, F.A. Soares & M.E.F. Costa. (2014) Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. Annals of Oncology 25:4, pages 831-836.
Crossref
Crossref
Fatima Cardoso, Joachim Bischoff, Etienne Brain, Ángel Guerrero Zotano, Hans-Joachim Lück, Vivianne C. Tjan-Heijnen, Minna Tanner & Matti Aapro. (2013) A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treatment Reviews 39:5, pages 457-465.
Crossref
Crossref
C. Campagnoli, P. Pasanisi, I. Castellano, C. Abbà, T. Brucato & F. Berrino. (2013) Postmenopausal breast cancer, androgens, and aromatase inhibitors. Breast Cancer Research and Treatment 139:1, pages 1-11.
Crossref
Crossref
Russell E. McDaniel, Philipp Y. Maximov & V. Craig Jordan. 2013. Hormones and Breast Cancer. Hormones and Breast Cancer
1
49
.
T. E. HickeyJ. L. L. Robinson, J. S. Carroll & W. D. Tilley. (2012) Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?. Molecular Endocrinology 26:8, pages 1252-1267.
Crossref
Crossref
Joseph P Garay, Bedri Karakas, Abde M Abukhdeir, David P Cosgrove, John P Gustin, Michaela J Higgins, Hiroyuki Konishi, Yuko Konishi, Josh Lauring, Morassa Mohseni, Grace M Wang, Danijela Jelovac, Ashani Weeraratna, Cheryl A Sherman Baust, Patrice J Morin, Antoun Toubaji, Alan Meeker, Angelo M De Marzo, Gloria Lewis, Andrea Subhawong, Pedram Argani & Ben H Park. (2012) The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Research 14:1.
Crossref
Crossref
MASATAKA SAWAKI, MASAKI WADA, YASUYUKI SATO, YUTAKA MIZUNO, HIRONOBU KOBAYASHI, KAZUKI YOKOI, MOTOI YOSHIHARA, KEITARO KAMEI, MOTOTSUGU OHNO & TSUNEO IMAI. (2012) High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase II study. Oncology Letters 3:1, pages 61-65.
Crossref
Crossref
Eric A. AriaziHeather E. Cunliffe, Joan S. Lewis-WambiMichael J. SlifkerAmanda L. Willis, Pilar Ramos, Coya Tapia, Helen R. Kim, Smitha YerrumCatherine G. N. SharmaEmmanuelle NicolasYoganand Balagurunathan, Eric A. RossV. Craig Jordan. (2011) Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proceedings of the National Academy of Sciences 108:47, pages 18879-18886.
Crossref
Crossref
V. Craig Jordan, Ifeyinwa Obiorah, Ping Fan, Helen R. Kim, Eric Ariazi, Heather Cunliffe & Hiltrud Brauch. (2011) The St. Gallen Prize Lecture 2011: Evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. The Breast 20, pages S1-S11.
Crossref
Crossref
V. Craig Jordan & Leslie G. Ford. (2011) Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A “New” Biology of Estrogen-induced Apoptosis. Cancer Prevention Research 4:5, pages 633-637.
Crossref
Crossref